Lymphoma & CLL Therapeutics

International T-cell Project: a subgroup analysis of patients with extranodal natural killer T-cell lymphoma

An analysis of data from a cohort of patients with ENKTL from the T-cell Project...

Non-myeloablative haploidentical or unrelated cord blood hematopoietic transplant for Hodgkin and non-Hodgkin lymphoma

A retrospective analysis comparing the outcomes of patients with HL or NHL who...

Update on CLL induction therapy

An interview with Astrid Pavlovsky, Fundaleu CHP, Buenos Aires, AR, on the first-line treatment of chronic lymphocytic leukemia (CLL).

The persistent immune dysregulation in survivors of DLBCL

The introduction of rituximab and subsequent novel therapies significantly improved clinical outcomes for patients with diffuse large B-cell...

Brentuximab vedotin receives positive CHMP opinion in combination with CHP as treatment for adult patients with previously untreated sALCL

On March 31, 2020, the European Medicines Agency’s (EMA)...

Review | Breast implant-associated anaplastic large cell lymphoma

A summary of the recently published review on breast implant-associated anaplastic large cell lymphoma by Antonio Marra and colleagues.

Nivolumab treatment followed by consolidation with allo-HSCT is associated with favorable outcomes in patients with relapsed/refractory Hodgkin lymphoma

Nivolumab is an immune checkpoint inhibitor...

KEYNOTE-087: 2-year follow-up of pembrolizumab in R/R classic Hodgkin lymphoma

KEYNOTE-087 is a multi-centre, single-arm, non-randomised phase II study of pembrolizumab in patients with R/R cHL.